

EQA round: E23/24 - Hormones 2

Deadline: 19.7.2024

Setup: groups - M (measurement principle), R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(393) C-peptide	[pmol/L]				9							5	4	80
Sample A		261	71	27	9							5	4	80
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		308	2,5	0,8	5	0	CVPG	307	7,7	20%	245	369	5	
Other					4	0							0	
							1x 4/12, 3x 4/179							
Sample B		455	110	23	9							5	4	80
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		524	4,2	0,79	5	0	CVPG	529	11	20%	423	635	5	
Other					4	0							0	
							1x 4/12, 3x 4/179							
(193) Ferritin	[µg/L]				14							13	13	100
Sample A												13	13	100
Other					14	0						13		
							3x 4/12, 4x 4/60, 1x 4/162, 2x 4/179, 3x 6/60, 1x 6/178							
Sample B												13	13	100
Other					14	0						13		
							3x 4/12, 4x 4/60, 1x 4/162, 2x 4/179, 3x 6/60, 1x 6/178							
(321) FSH	[U/L]				8							8	7	88
Sample A												8	7	88
Other					8	0						8		
							4x 4/12, 4x 4/60							
Sample B												8	7	88
Other					8	0						8		
							4x 4/12, 4x 4/60							
(328) hGH	[mU/L]				4							4	4	100
Sample A												4	4	100
Other					4	0						4		
							2x 4/12, 2x 4/29							
Sample B												4	4	100
Other					4	0						4		
							2x 4/12, 2x 4/29							
(329) IGF-1	[µg/L]				5							5	5	100
Sample A												5	5	100
Other					5	0						5		
							3x 4/29, 2x 4/60							
Sample B												5	5	100
Other					5	0						5		
							3x 4/29, 2x 4/60							
(392) IGF-BP3	[µg/L]				2							2	2	100
Sample A												2	2	100
Other					2	0						2		
							1x 4/29, 1x 4/60							
Sample B												2	2	100
Other					2	0						2		
							1x 4/29, 1x 4/60							
(325) Insulin	[mU/L]				6							6	6	100
Sample A												6	6	100
Other					6	0						6		
							1x 4/12, 3x 4/60, 2x 4/179							
Sample B												6	6	100
Other					6	0						6		
							1x 4/12, 3x 4/60, 2x 4/179							
(326) Folate	[nmol/L]				13							13	13	100
Sample A		13,1	4,3	33	13							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		13	6,4	49	7	0	CVPG	15,7	1,2	27%	11,4	20	0	
Other					6	0							0	
							3x 4/12, 3x 4/179							
Sample B		50	6,4	13	13							13	13	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		44,3	1,7	3,8	7	0	CVPG	45,4	0,012	27%	33,1	57,7	7	
Other					6	0							6	
							3x 4/12, 3x 4/179							
(320) LH	[U/L]				8							8	8	100
Sample A												8	8	100
Other					8	0						8		
							4x 4/12, 4x 4/60							
Sample B												8	8	100

EQA round: E23/24 - Hormones 2

Deadline: 19.7.2024

Setup: groups - M (measurement principle), R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Other					8	0	4x 4/12, 4x 4/60					8		
(405) Parathyrin intact (PTH)	[pmol/L]				10							10	7	70
Sample A		0,576	0,31	54	10							10	8	80
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		0,638	0,21	33	7	0	CVPG	0,663	0,017 ±0,276	0,387	0,939	7		
Other					3	0	3x 4/12					3		
Sample B		5,04	1	20	10							10	8	80
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		4,59	0,34	7,4	7	0	CVPG	4,49	0,03	23%	3,45	5,53	7	
Other					3	0	3x 4/12					3		
(322) Prolactin	[mU/L]				8							8	8	100
Sample A		184	32	18	8							8	8	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		205	2,4	1,2	5	0	CVPG	201	1,3	16%	168	234	5	
Other					3	0	3x 4/12					3		
Sample B		218	35	16	8							8	8	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		236	7,7	3,2	5	0	CVPG	236	1,5	16%	198	274	5	
Other					3	0	3x 4/12					3		
(390) Renin	[ng/L]				3							1	1	100
Sample A												1	1	100
Other					3	0	1x 1/185, 1x 4/73, 1x 4/164					1		
Sample B												1	1	100
Other					3	0	1x 1/185, 1x 4/73, 1x 4/164					1		
(394) SHBG	[nmol/L]				6							6	6	100
Sample A												6	6	100
Other					6	0	1x 4/12, 4x 4/60, 1x 4/179					6		
Sample B												6	6	100
Other					6	0	1x 4/12, 4x 4/60, 1x 4/179					6		
(327) Vitamin B₁₂	[pmol/L]				13							13	12	92
Sample A		220	60	27	13							13	12	92
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		263	42	16	7	0	CVPG	271	2,3	20%	216	326	7	
Other					6	0	3x 4/12, 3x 4/179					6		
Sample B		319	63	20	13							13	12	92
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		344	39	11	7	0	CVPG	363	2,4	20%	290	436	7	
Other					6	0	3x 4/12, 3x 4/179					6		
(319) Vitamin B₁₂ (active)	[pmol/L]				3							0		
Sample A												0		
Other					3	0	3x 4/60					0		
Sample B												0		
Other					3	0	3x 4/60					0		